STOCK TITAN

Ligand Pharms CVR (LGNDZ) Stock Price, News & Analysis

LGNDZ OTC
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
46 67 sessions, October 27, 2025 to October 30, 2026
Largest daily move
-66.7% close of February 19, 2026
1-year change
-72.1% closing prices, October 27, 2025 to October 30, 2026
1-month change
-25.3% closing prices, September 16, 2026 to October 30, 2026

Company Description

LGNDZ declined 72.1% in the 12 months to October 30, 2026. The last closing price was $0.0017.

For FY2025, Ligand Pharms CVR reported revenue of $268.1M with net income of $124.5M and diluted earnings per share of $6.13. The company operates at a net profit margin of 46.4%.

This page collects what Stock Titan holds for LGNDZ, including price data, SEC filings, insider trading activity, financial highlights, and short interest trends.

Stock Performance

$0.0017
No recent trading
Last close: October 30, 2026
-72.1%
1 year to October 30, 2026

Ligand Pharms CVR (LGNDZ) closed at $0.0017 on October 30, 2026. In the 12 months to October 30, 2026, the price lost 72.1%.

See what a $1,000 investment in LGNDZ was worth at its last close

LGNDZ Metrics & Rankings

Price returns through October 30, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

No recent news available for LGNDZ.

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
24,093
Shares Sold
40
Transactions
Most Recent Transaction
KOZARICH JOHN W (Director) sold 500 shares @ $325.00 on November 12, 2026

Insider selling at Ligand Pharms CVR over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Ligand Pharms CVR generated $268.1M in revenue in FY2025, operating income reached $41.0M (15.3% operating margin), and net income was $124.5M, reflecting a 46.4% net profit margin. Diluted earnings per share stood at $6.13. The company generated $49.4M in operating cash flow. The current ratio was 22.23, measuring current assets divided by current liabilities.

$268.1M
Revenue (FY2025)
$124.5M
Net Income (FY2025)
$49.4M
Operating Cash Flow

Upcoming Events

No upcoming events scheduled for LGNDZ.

Short Interest History

Last 12 Months

Short interest in Ligand Pharms CVR (LGNDZ) currently stands at 25 shares, representing 0.0% of the shares outstanding.

Days to Cover History

Last 12 Months

Days to cover for Ligand Pharms CVR (LGNDZ) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume.

Frequently Asked Questions

Ligand Pharms CVR (LGNDZ) has no recent trading. Its last close was $0.0017 on October 30, 2026.

The FY2025 revenue of Ligand Pharms CVR (LGNDZ) is $268.1M, from its most recent completed fiscal year.

The FY2025 net income of Ligand Pharms CVR (LGNDZ) is $124.5M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Ligand Pharms CVR (LGNDZ) is $6.13 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Ligand Pharms CVR (LGNDZ) is $49.4M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Ligand Pharms CVR (LGNDZ) is 46.4% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Ligand Pharms CVR (LGNDZ) is 15.3% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The current ratio of Ligand Pharms CVR (LGNDZ), current assets divided by current liabilities, was 22.23 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Ligand Pharms CVR (LGNDZ) is $41.0M for FY2025, its most recent completed fiscal year. Learn about operating income.